Omeros Corporation
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Last updated:

Abstract:

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Status:
Application
Type:

Utility

Filling date:

4 Aug 2020

Issue date:

18 Feb 2021